About MediWound
MediWound is a company based in Yavne (Israel) founded in 2001 by Lior Rosenberg. MediWound has raised $18 million across 6 funding rounds from investors including Clal Biotechnology Industries, MTEC and Point72. The company has 111 employees as of December 31, 2024. MediWound has completed 1 acquisition, including PolyHeal. MediWound offers products and services including NexoBrid, EscharEx, and MW005. MediWound operates in a competitive market with competitors including Ilya Pharma, QBiotics, Resolution Therapeutics, SanuWave and Haemostatix, among others.
- Headquarter Yavne, Israel
- Employees 111 as on 31 Dec, 2024
- Founders Lior Rosenberg
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Mediwound Ltd.
-
Annual Revenue
$20.22 M (USD)8.22as on Dec 31, 2024
-
Net Profit
-$30.22 M (USD)-350.03as on Dec 31, 2024
-
EBITDA
-$17.9 M (USD)-26.07as on Dec 31, 2024
-
Total Equity Funding
$18 M (USD)
in 6 rounds
-
Latest Funding Round
$17.71 M (USD), Grant
Jul 16, 2024
-
Investors
Clal Biotechnology Industries
& 10 more
-
Employee Count
111
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of MediWound
MediWound is a publicly listed company on the NASDAQ with ticker symbol MDWD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of MediWound
MediWound offers a comprehensive portfolio of products and services, including NexoBrid, EscharEx, and MW005.
Enzymatic product for removing nonviable burn tissue safely.
Therapy for debriding chronic wounds and promoting healing.
Topical biologic for treating low-risk basal cell carcinoma.
People of MediWound
Unlock access to complete
Unlock access to complete
Funding Insights of MediWound
MediWound has successfully raised a total of $18M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $17.71 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MediWound
MediWound has secured backing from 11 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Clal Biotechnology Industries, MTEC and Point72.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments in healthcare are focused on by aMoon.
|
Locked | Locked | Locked |
Investor details for MediWound
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MediWound
MediWound has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include PolyHeal.
Investment portfolio details for MediWound
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Microsphere-based technology is utilized for active wound healing products.
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for MediWound
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - MediWound
Detailed financials for MediWound
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mediwound Comparisons
Peer comparison for MediWound
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MediWound
MediWound operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ilya Pharma, QBiotics, Resolution Therapeutics, SanuWave and Haemostatix, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biological drugs for skin and mucosa wound treatment are developed.
|
|
| Locked | Locked | Locked |
Small molecules from plant extracts are developed for medical applications.
|
|
| Locked | Locked | Locked |
Macrophage cell therapies are developed for inflammatory and liver diseases.
|
|
| Locked | Locked | Locked |
Noninvasive devices and biologics for wound healing are developed.
|
|
| Locked | Locked | Locked |
Developing new class of peptide based coagulant
|
Detailed competitors of MediWound
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mediwound
Complete news archive for MediWound
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MediWound
MediWound was founded in 2001 and raised its 1st funding round 12 years after it was founded.
MediWound is headquartered in Yavne, Israel. It is registered at Yavne, Central District, Israel.
Gal Cohen is the current CEO of MediWound.
MediWound is a funded company, having raised a total of $18M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at MediWound is 111.
Annual revenue of MediWound is $20.22M as on Dec 31, 2024.
MediWound was founded in 2001 in Yavne, Israel, within the biotechnology sector. Enzymatic technologies are utilized to create therapies for wound care, burns, and tissue regeneration. Products such as NexoBrid for burn debridement, EscharEx for chronic wounds, and MW005 for non-melanoma skin cancers are included in the portfolio. Operations focus on biological medicinal products for dermatological applications.
MediWound's top competitors include Ilya Pharma, SanuWave and QBiotics.
MediWound offers NexoBrid, EscharEx, and MW005.
Yes, MediWound is publicly traded on NASDAQ under the ticker symbol MDWD.
MediWound has made 1 acquisition, including PolyHeal.
MediWound has 11 investors. Key investors include Clal Biotechnology Industries, MTEC, Point72, Deep Insight, and Israel Biotech Fund.
The ticker symbol of MediWound is MDWD on NASDAQ.